Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00541_DB00701_nanopub.RA5j5HaUA8nK2bSOPpOP91ieqHF9PjMNLp6x7daPrgrNU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00541_DB00701 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00541_DB00701 label "DDI between Vincristine and Amprenavir - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB00541_DB00701]" assertion.
- drugbank_resource:DB00541_DB00701 identifier "drugbank_resource:DB00541_DB00701" assertion.
- drugbank_resource:DB00541_DB00701 title "DDI between Vincristine and Amprenavir - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed." assertion.
- drugbank:DB00541 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00541_DB00701 assertion.
- drugbank:DB00701 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00541_DB00701 assertion.